1315 Capital completed the acquisition of Primrose Bio.

1315 Capital, a private investment firm, completed the acquisition of Primrose Bio, a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines. Financial terms were not disclosed. "We are thrilled to have the support of such a high-quality organization and team at 1315 Capital who share our vision of expanding opportunities in biomanufacturing technologies for the pharmaceutical industry. With this investment, we are well-positioned to advance our therapeutic protein and nucleic acid manufacturing solutions with our existing large-pharma collaborators and future partners," Helge Zieler, Primrose CEO.